
Commentary|Videos|May 30, 2025
CMSC Live: 2025 Annual Meeting Day 3
Host Jeffrey Wilken, PhD, chats with Riley Bove, MD, about the third day of the 2025 CMSC Annual Meeting in Phoenix, Arizona.
Advertisement
Host
- Jeffrey Wilken, PhD
President-Elect,Consortium of Multiple Sclerosis Centers (CMSC); assistant professor of neurology, Georgetown University; director of Research, Neuropsychology Associates of Fairfax; executive director, Washington Neuropsychology Research Group
Guest
- Riley Bove, MD
Associate Professor of Neurology at the University of California, San Francisco; Neurologist, UCSF Weill Institute for Neurosciences
Segment Breakdown
- 00:00 – Jeffrey Wilken, PhD, welcomes viewers to CMSC Day 3, introduces Riley Bove, MD, and highlights her lecture on women’s health in MS—covering pregnancy, lactation, and menopause—calling attention to the lack of coverage in prior meetings
- 01:00 – Riley Bove, MD, explains how reproductive milestones in women with MS can be managed proactively with guidance and care, emphasizing gender-specific biological considerations and medication planning.
- 03:30 – Discussion shifts to MS treatment during pregnancy. Riley Bove, MD, explains that treatment isn’t necessarily halted now; rather, medication use is personalized to minimize fetal risk and maintain disease control.
- 05:00 - Riley Bove, MD, discusses disparities in guideline adoption, noting that while newer providers are being trained in reproductive health in MS, many community clinicians still operate under outdated practices.
- 07:45 - Riley Bove, MD, revisits the controversial history of HRT, clarifies its benefits for perimenopausal symptoms and bone health, and explains how previous studies misled the medical community.
- 10:30 - Riley Bove, MD, highlights growing concerns in men’s mental health, emotional development, and healthcare access—especially in young men—framing it as a parallel issue to under-addressed women’s health.
- 13:15 - Riley Bove, MD, shares her appreciation for the CMSC's comprehensive and collaborative environment, especially its interdisciplinary approach to MS care.
- 14:00 - Jeffrey Wilken, PhD, thanks Riley Bove, MD, for her insightful lecture and interview, and both express their positive experiences at the meeting.
Advertisement
Related to this article

Findings from the phase 3 METEOROID trial showed that satralizumab reduced the risk of relapse in patients with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease.

The associate vice president of clinical research at the Parkinson's Foundation discussed a large-scale replication of rs3115534-G, a noncoding GBA1 variant tied to Parkinson disease in people of African ancestry.

Leonard Dragone, MD, PhD, Disease Area Leader at Johnson & Johnson, discusses how nipocalimab is being incorporated into generalized MG care, what long-term data show, and where J&J sees the therapy’s role evolving.

Pivotal AFFINITY DUCHENNE results showed microdystrophin expression above the prespecified threshold in 93% of evaluable participants, with preliminary functional findings favoring treatment over external controls.

Three-year extension data from the phase 3 IB1001-301 trial show levacetylleucine slowed disease progression in both adults and children with Niemann-Pick disease type C.

The phase 1 ASCEND trial is testing a single intrathecal dose of the investigational AAV9 gene therapy INS1201 in young boys with Duchenne muscular dystrophy.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Autoinjector for Self-Administered Zilucoplan in Generalized Myasthenia Gravis
2
Arimoclomol Plus Miglustat Shows Early, Sustained Slowing of Niemann-Pick Disease Type C Progression
3
New Phase 1 Study Tests Intrathecal Gene Therapy Agent INS1201 in Duchenne Muscular Dystrophy
4
TSHA-102 Produces Multidomain Functional Gains in Rett Syndrome
5

